Background: Phase 3 studies of immune checkpoint inhibitors have not shown a survival benefit in prostate cancer. but some patients have a profound anticancer response. Patients and Methods: We evaluated the efficacy of the CTLA-4 targeted agent. ipilimumab. https://setartradinges.shop/product-category/cowboy-hat/